By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced it has renewed its microfluidic chip supply agreement with Agilent Technologies.

Under a new seven-year agreement, Caliper will remain the exclusive supplier of microfluidic chips to Agilent for use on its Bioanalyzer 2100 platforms. Since its launch in 1999, more than 7,000 Bioanalyzer 2100 instruments have been sold, and Caliper has supplied about 5 million chips for use on the platform, Caliper said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.